Dr. John Scribner Schieffelin, MD

Dr. Schieffelin practices at Lakeview Regional Medical Center in Covington, Louisiana.

Dr. Schieffelin's NPI, 1194995936, was assigned on March 7, 2008. Dr. Schieffelin graduated from Tulane University School of Medicine in 2001. Dr. Schieffelin holds Louisiana license 025654.

Dr. Schieffelin's primary practice is Lakeview Regional Medical Center, at 95 Judge Tanner Blvd, Covington, LA 70433 in Saint Tammany Parish. The practice phone is (504) 503-4000.

Dr. Schieffelin's primary practice is Lakeview Regional Medical Center in Covington, Louisiana. Dr. Schieffelin is also affiliated with East Jefferson General Hospital. The medical group on file is Ochsner Health. Dmand AI also links Dr. Schieffelin to 1 more hospital, 2 medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Schieffelin practices, 3 sites in all. Vendor and product names are available with a free account.

Infectious disease is Dr. Schieffelin's primary specialty in the NPI Registry, under taxonomy code 207RI0200X. Dr. Schieffelin is licensed in Louisiana.

CMS data shows 12 Medicare services from Dr. Schieffelin across 1 procedure code in 2022, for 18 Medicare patients. Medicare paid $681 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 18 Medicare patients who saw Dr. Schieffelin in 2024. 75% of them have high blood pressure, and 67% have high cholesterol. Their average risk score is 3.25, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Schieffelin's median patient age at 61, with 51% women.

In 2024, Dr. Schieffelin wrote 456 Medicare Part D claims for 32 patients. 61% of them were for generic drugs. CMS names the drug for 287 of them, across 14 drugs with 11 or more claims each, at $595,312 in total drug cost. In 2023, CMS named 254 claims across 13 drugs.

Dr. Schieffelin accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 107 papers to Dr. Schieffelin, published from 2010 to 2025. 2020 was the busiest year, with 11. The most frequent topics are Hemorrhagic Fever, Ebola, Sierra Leone and Lassa Fever. Dr. Schieffelin has published most often in Am J Trop Med Hyg. Dr. Schieffelin's most frequent co-authors are Colleen Suzanne Kraft, MD, Susan L F McLellan, MD and Stacy Schmidt Drury, MD, PhD.

Dmand AI links Dr. Schieffelin to 1 clinical trial. 1 is still active or recruiting. Conditions studied include COVID-19 and Pneumonia, Viral.

CMS Open Payments shows 20 general payments to Dr. Schieffelin from 8 drug and device companies from 2016 to 2024. Food and beverage make up the largest share, 89% of the total. Gilead Sciences, Inc. paid the most, $133.

Dr. Schieffelin graduated from Tulane University School of Medicine in 2001.